B
Bull
Bull · 25%NBY
$0.46
Szenariopreis
$1.950
+0.441 (+22.64%)Zum Schluss
Loading chart…
- High
- 1.980
- Open
- 1.580
- VWAP
- 1.83
- Vol
- 637.60K
- Mkt Cap
- 3.29M
- Low
- 1.570
- Amount
- 1.17M
- EV/EBITDA, TTM
- 0.00
NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
AI analysis of NovaBay Pharmaceuticals Inc (NBY)
holdNovaBay Pharmaceuticals Inc (NBY) is not a strong buy for a beginner investor seeking long-term growth. Despite the recent price surge, the lack of positive financial performance, absence of strong trading signals, and neutral sentiment from hedge funds and insiders suggest that this stock does not align with the user's investment goals.
Analyst Ratings (4)
Buy
4 Buy
0 Hold
0 Sell
Current: 1.95
Tief
—
Durchschnitt
—
Hoch
—
Ascendiant Capital
Strong Buy
$0.85
2024-11-11
Ascendiant Capital
2024-11-11
Kursziel
$0.85
Strong Buy
Ascendiant Capital
Strong Buy
$4900
2022-05-20
Ascendiant Capital
2022-05-20
Kursziel
$4900
Strong Buy
Roth Capital
Hold
—
2018-03-26
Roth Capital
2018-03-26
Kursziel
—
Hold
Roth Capital
Strong Buy
$193
2017-06-05
Roth Capital
2017-06-05
Kursziel
$193
Strong Buy
Ascendiant Capital
Strong Buy
$68906
2013-03-06
Ascendiant Capital
2013-03-06
Kursziel
$68906
Strong Buy
Bewertungskennzahlen
The current forward P/E ratio for NovaBay Pharmaceuticals Inc (NBY) is 42.02, compared to its 5-year average forward P/E of 19.49.
Alphio AI Price Scenarios for NBY
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
8.503-23seekingalphaNovaBay Pharmaceuticals Rebrands to Stablecoin Development Corporation
9.501-21BenzingaNetflix Reports Q4 Results, Q1 Guidance Misses Estimates
9.501-20BenzingaD.R. Horton Reports Q1 Net Income of $594.8M Exceeding Estimates
8.501-20seekingalphaNovaBay Pharmaceuticals (NBY) Announces $100M Stock Sale Agreement with Virtu Americas
9.501-16BenzingaJ.B. Hunt Reports Q4 Revenue Slightly Below Estimates, Shares Drop 4.2%
NBY FAQ — answered by Alphio AI
NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
NovaBay Pharmaceuticals Inc (NBY) is not a strong buy for a beginner investor seeking long-term growth. Despite the recent price surge, the lack of positive financial performance, absence of strong trading signals, and neutral sentiment from hedge funds and insiders suggest that this stock does not align with the user's investment goals.
4 analysts cover NBY: 4 rate it Buy, 0 Hold and 0 Sell.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.